Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA:688266)

SHA:688266 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	2,070	2,154	2,110	797.05	1,137	1,150
Trading Asset Securities	16.2	40.5	137.02	248.93	65.26	449.85
Cash & Short-Term Investments	2,086	2,194	2,247	1,046	1,202	1,600
Cash Growth	-5.32%	-2.34%	114.79%	-12.97%	-24.86%	2093.61%
Accounts Receivable	178.32	143.63	101.14	88.99	62.37	-
Other Receivables	10.47	9.38	10.89	12.51	12.45	2.62
Receivables	188.8	153.01	112.03	101.5	74.82	2.62
Inventory	174.37	182.86	110.85	98.98	51.91	23.14
Prepaid Expenses	-	-	-	-	-	0.39
Other Current Assets	56.3	45.85	50.79	45.3	77.33	43.83
Total Current Assets	2,506	2,576	2,520	1,292	1,406	1,670
Property, Plant & Equipment	456.8	363.43	271.21	247.09	188.91	91.03
Long-Term Investments	-	-	5.99	10	10	10
Other Intangible Assets	35.48	50.01	69.27	91.03	116.29	129.51
Long-Term Deferred Charges	7.3	11.39	16.39	20.96	13.03	4.35
Other Long-Term Assets	7.88	3.88	4.02	7.48	11.78	65.82
Total Assets	3,013	3,005	2,887	1,668	1,746	1,970
Accounts Payable	223.89	197.1	137.73	151.72	118.19	64.96
Accrued Expenses	62.43	86.22	82.02	67.5	48.22	30.92
Short-Term Debt	966.94	951.86	795.16	390.79	131.81	17.67
Current Portion of Long-Term Debt	22.66	4.97	50.56	50.04	30.03	-
Current Portion of Leases	-	11.2	13.17	13.69	13.55	-
Current Income Taxes Payable	41.7	20.95	20.64	20.29	18.58	16.94
Current Unearned Revenue	1.7	-	-	0.28	0.36	-
Other Current Liabilities	35.52	101.15	35.89	34.88	20.16	10.38
Total Current Liabilities	1,355	1,373	1,135	729.19	380.89	140.88
Long-Term Debt	125.7	44.35	-	50.09	-	30.03
Long-Term Leases	10.36	26.86	29.46	43.18	48.18	4.32
Long-Term Unearned Revenue	2.87	9.2	11.55	45.04	48.05	83.66
Long-Term Deferred Tax Liabilities	2.65	5.7	9.58	13.32	15.77	19.81
Other Long-Term Liabilities	367.92	292.45	56.6	-	-	-
Total Liabilities	1,864	1,752	1,242	880.82	492.88	278.69
Common Stock	264.71	264.71	264.71	240	240	240
Additional Paid-In Capital	3,109	3,120	3,353	2,222	2,205	2,174
Retained Earnings	-2,210	-2,117	-1,979	-1,700	-1,243	-791.56
Comprehensive Income & Other	-15.01	-14.47	-5.95	-2.84	-6.32	-5.04
Total Common Equity	1,149	1,254	1,633	759.12	1,196	1,618
Minority Interest	-	-1.26	11.98	28.37	56.76	73.86
Shareholders' Equity	1,149	1,253	1,645	787.49	1,253	1,692
Total Liabilities & Equity	3,013	3,005	2,887	1,668	1,746	1,970
Total Debt	1,126	1,039	888.35	547.8	223.57	52.02
Net Cash (Debt)	960.79	1,155	1,358	498.18	978.32	1,548
Net Cash Growth	-24.97%	-14.97%	172.65%	-49.08%	-36.78%	19021.89%
Net Cash Per Share	3.60	4.36	5.31	2.08	4.08	6.59
Filing Date Shares Outstanding	264.71	264.71	264.71	264.49	240	240
Total Common Shares Outstanding	264.71	264.71	264.71	240	240	240
Working Capital	1,151	1,202	1,385	562.57	1,025	1,529
Book Value Per Share	4.34	4.74	6.17	3.16	4.98	6.74
Tangible Book Value	1,114	1,204	1,564	668.09	1,080	1,488
Tangible Book Value Per Share	4.21	4.55	5.91	2.78	4.50	6.20
Buildings	-	135.26	41.93	41.93	41.21	-
Machinery	-	145.53	120.48	121.74	96.02	-
Construction In Progress	-	123.47	135.83	86.67	27.25	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.